Rexahn Pharmaceuticals, Inc. (RNN) Announces Initial Results From Phase I Trial Of Supinoxintm (RX-5902) For Solid Cancer Tumors
3/11/2014 9:08:41 AM
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company announced today initial data for the Phase I dose-escalation clinical trial of SupinoxinTM (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors.
Help employers find you! Check out all the jobs and post your resume.
comments powered by